To Issue 189
Citation: “Company Showcase: Grand River Aseptic Manufacturing”, ONdrugDelivery, Issue 189 (Sep 2026), pp 28.
Grand River Aseptic Manufacturing (GRAM) discusses its sterile filling capabilities and how its expanding facilities support growing demand for vial, syringe and cartridge filling.
Grand River Aseptic Manufacturing’s (GRAM’s) operations are focused on a strong commitment to sterile filling. GRAM prioritises patient safety by adhering to strict aseptic standards and collaborating closely with each client, using its extensive expertise to generate optimal outcomes.
GRAM’s Sterile Filling Facility One opened in 2020 and features production lines approved by both the EU and the US FDA. The facility has the capacity to produce over 80 million vials as well as more than 10 million syringes and cartridges per year.
Sterile Filling Facility Two is the company’s newest sterile filling facility, equipped to provide over 50 million units of syringe and cartridge filling capacity annually, starting with Line 5 (Table 1). This facility includes the infrastructure needed for future expansion to support client needs and meet market demand.
| Line 1: Liquid & Lyophilised Vials | Line 2: Liquid Vials | Line 3: Prefilled Syringes & Cartridges |
| • Bausch+Ströbel • SKAN isolator • 4-head • IMA lyophiliser • 2R, 6R, 10R, 20R, 50R • 20 million units/yr • 6,200 lyo hr/yr • EU/FDA approved |
• Bausch+Ströbel • SKAN isolator • 4-head • 2R, 6R, 10R, 20R, 25R • Up to 12,000 units/hr • 20–25 million units/yr • Identical to Line 1 • EU/FDA approved |
• Bausch+Ströbel • SKAN isolator • 1/2-head • PFS: 1, 2.25, 3 mL • Cartridges: 3, 5, 10, 20 mL • 1,000–3,000 units/hr • 8–10 million units/yr • EU/FDA approved |
| Line 4: Liquid Vials | Line 5: Prefilled Syringes & Cartridges | Available Future Space |
| • Bausch+Ströbel • SKAN isolator • 8-head • 2R, 6R, 10R • External vial washer • 24,000 units/hr • 40–50 million units/yr |
• Groninger • SKAN isolator • 10-head • PFS: 1, 2.25, 3 mL • Cartridges: 5, 10 mL • 24,000 units/hr • 40–50 million units/yr • Media Runs Q1 2027 |
Space and utilities to support three additional fill lines and client-dedicated projects
|
Table 1: GRAM’s fill-finish lines.
“FOR PHARMACEUTICAL COMPANIES, CHOOSING A CDMO GOES BEYOND ASSESSING CAPACITY; IT IS ABOUT FINDING A PARTNER COMMITTED TO QUALITY AND INNOVATION.”
For pharmaceutical companies, choosing a CDMO goes beyond assessing capacity; it is about finding a partner committed to quality and innovation. GRAM is dedicated to delivering consistent, high-quality sterile fill-finish services that empower pharmaceutical companies in their mission to improve patient outcomes. Specialising in biologics, GRAM’s five filling lines serve pharma’s liquid or lyophilised vial, syringe and cartridge products.
